ABVCHealthcare · BiotechnologyABVC Stock Forecast: ABVC BioPharma, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 22 Aug 2026 — in the weakest quartile.
ABVC stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores ABVC BioPharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (88): Smaller than most of the companies we track.
Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
ABVC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ABVC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Nov 2022 | Maxim Group | Downgrade | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABVC appears on the weeks it earns a place.
ABVC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
ABVC BioPharma, Inc. (ABVC) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.0×
- Price / sales
- —
- Price / book
- 2.2×
- EV / EBITDA
- −4.3×
Cheaper than 75% of US stocks
Cheaper than 44% of US stocks
Cheaper than 77% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 1% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −69.9%
- Return on assets
- −22.9%
- Dividend yield
- —
Higher than 17% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ABVC vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ABVC BioPharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about ABVC stock
How does Ticker Nerd's model rank ABVC?
As at 22 Aug 2026, ABVC BioPharma, Inc. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (88 of 100).
What is the ABVC stock forecast for 2030?
No analyst covering ABVC BioPharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABVC are extrapolating price history, which says nothing about the business.
How has ABVC stock performed over the past year?
ABVC BioPharma, Inc. returned -70.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does ABVC BioPharma, Inc. do?
ABVC BioPharma Inc. is a clinical-stage biopharmaceutical company that identifies, in-licenses, and develops plant-derived compounds and medical devices to address unmet medical needs.
About ABVC BioPharma, Inc.
ABVC BioPharma Inc. is a clinical-stage biopharmaceutical company that identifies, in-licenses, and develops plant-derived compounds and medical devices to address unmet medical needs. It focuses on natural, plant-based medications targeting severe conditions in areas such as ophthalmology, central nervous system disorders, attention deficit hyperactivity disorder, depression, oncology, hematology, and more. Key pipeline candidates include ABV-1504 for major depressive disorder, which has completed Phase II trials; ABV-1505 for adult ADHD in Phase II; ABV-1701 Vitargus for retinal diseases in Phase II; and others like ABV-1501 for triple negative breast cancer, ABV-1702 for myelodysplastic syndromes, and ABV-1519 for non-small cell lung cancer, spanning Phase I/II to II trials. The company partners with global research institutions and seeks collaborations with large pharmaceutical firms for late-stage development and commercialization after Phase II success. Through its subsidiary BioKey, Inc., it provides contract development and manufacturing services for nutritional and pharmaceutical products. Founded in 2015 and headquartered in Fremont, California, ABVC BioPharma Inc. advances a growing portfolio supported by trials in multiple countries including the United States, Thailand, Australia, and Taiwan.
CEO Dr. Uttam Yashwant Patil Ph.D. · 16 employees · United States · https://www.abvcpharma.com